Aquestive Therapeutics Inc. is a pharmaceutical company specializing in proprietary drug delivery technologies to advance orally administered medicines. It develops products that deliver complex molecules, offering non-invasive alternatives to traditional invasive therapies like injections. The company manufactures and exclusively supplies four commercialized products marketed by licensees in the United States and internationally, including Suboxone® Sublingual Film, Sympazan® Oral Film, Ondif® Oral Film, and royalty-based products such as Azstarys®. Aquestive Therapeutics Inc. leverages its PharmFilm® platform in collaborations with pharmaceutical partners to develop and commercialize new molecules. Its pipeline features late-stage Anaphylm™ (dibutepinephrine) Sublingual Film for treating severe allergic reactions like anaphylaxis, part of the AdrenaVerse™ epinephrine prodrug platform, alongside AQST-108 topical gel for dermatologic conditions and Libervant® (diazepam) Buccal Film for acute seizure clusters in epilepsy patients. Operating in the medicinal manufacturing sector, Aquestive Therapeutics Inc. emphasizes patient-friendly formats that dissolve quickly without water, enhancing accessibility for allergy and neurology treatments.